Summary of medicine characteristics - OGIVRI 150 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THEAUTHORISATION
01/01/2021
01/01/2021
Sources: Original (products.mhra.gov.uk)
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS in ATC
L01XC Monoclonal antibodies, antineoplastic
L01XC03 trastuzumab